392 related articles for article (PubMed ID: 25967123)
1. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
[TBL] [Abstract][Full Text] [Related]
2. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
[TBL] [Abstract][Full Text] [Related]
3. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
Courbon G; Martinez-Calle M; David V
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
[TBL] [Abstract][Full Text] [Related]
5. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
[TBL] [Abstract][Full Text] [Related]
6. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD
Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773
[TBL] [Abstract][Full Text] [Related]
7. Update on fibroblast growth factor 23 in chronic kidney disease.
Wolf M
Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
[TBL] [Abstract][Full Text] [Related]
8. Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis.
Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Chen HY; Yang JY; Ko MJ; Pai MF; Tu YK; Hung KY; Chien KL
Nephrol Dial Transplant; 2018 Nov; 33(11):1977-1983. PubMed ID: 29420827
[TBL] [Abstract][Full Text] [Related]
9. FGF23: a mature renal and cardiovascular risk factor?
Zoccali C; Yilmaz MI; Mallamaci F
Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
[TBL] [Abstract][Full Text] [Related]
10. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
Vogt I; Haffner D; Leifheit-Nestler M
Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
[TBL] [Abstract][Full Text] [Related]
11. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
Isakova T; Barchi-Chung A; Enfield G; Smith K; Vargas G; Houston J; Xie H; Wahl P; Schiavenato E; Dosch A; Gutiérrez OM; Diego J; Lenz O; Contreras G; Mendez A; Weiner RB; Wolf M
Clin J Am Soc Nephrol; 2013 Jun; 8(6):1009-18. PubMed ID: 23471131
[TBL] [Abstract][Full Text] [Related]
12. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
[TBL] [Abstract][Full Text] [Related]
13. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
14. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Balani S; Perwad F
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
[TBL] [Abstract][Full Text] [Related]
15. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
[TBL] [Abstract][Full Text] [Related]
16. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.
Czaya B; Faul C
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461904
[TBL] [Abstract][Full Text] [Related]
17. New insights into the FGF23-Klotho axis.
Olauson H; Vervloet MG; Cozzolino M; Massy ZA; Ureña Torres P; Larsson TE
Semin Nephrol; 2014 Nov; 34(6):586-97. PubMed ID: 25498378
[TBL] [Abstract][Full Text] [Related]
18. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
19. Klotho/FGF23 Axis in CKD.
Tsuchiya K; Nagano N; Nitta K
Contrib Nephrol; 2015; 185():56-65. PubMed ID: 26023015
[TBL] [Abstract][Full Text] [Related]
20. Phosphate and FGF23 in the renoprotective benefit of RAAS inhibition.
de Seigneux S; Martin PY
Pharmacol Res; 2016 Apr; 106():87-91. PubMed ID: 26900884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
